Strategies and challenges for the next generation of therapeutic antibodies. - sprookjes - yvandenbroek - TriplyDB

Strategies and challenges for the next generation of therapeutic antibodies.

Strategies and challenges for the next generation of therapeutic antibodies.

http://www.wikidata.org/entity/Q34111699

about

Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tag Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo The expanding role of immunopharmacology: IUPHAR Review 16 Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics Nucleic acid aptamers: an emerging frontier in cancer therapy Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs Evaluation of current cancer immunotherapy: hemato-oncology Monoclonal antibodies for the treatment of cancer Fluorescently-tagged anti-ganglioside antibody selectively identifies peripheral nerve in living animals.Bispecific digoxigenin-binding antibodies for targeted payload delivery Rationalization and Design of the Complementarity Determining Region Sequences in an Antibody-Antigen Recognition Interface Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development Synthetic approach to the generation of antibody diversity A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy Aptamer-Drug Conjugates Experimental and in silico modelling analyses of the gene expression pathway for recombinant antibody and by-product production in NS0 cell lines Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity Extremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein Scaffold Derivative of Extremophilic 50S Ribosomal Protein L35Ae as an Alternative Protein Scaffold Generation of Novel Hybrid Aptamer-Molecularly Imprinted Polymeric Nanoparticles MERS-CoV spike protein: a key target for antivirals.Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation VH-VL orientation prediction for antibody humanization candidate selection: A case study.MoFvAb: Modeling the Fv region of antibodies.Molecular Imaging of Pancreatic Cancer with Antibodies.Investigating Structure and Dynamics of Proteins in Amorphous Phases Using Neutron Scattering.World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines.The glycan role in the glycopeptide immunogenicity revealed by atomistic simulations and spectroscopic experiments on the multiple sclerosis biomarker CSF114(Glc)High-throughput profiling of N-linked oligosaccharides in therapeutic antibodies using a microfluidic CD platform and MALDI-MS.Observation of small cluster formation in concentrated monoclonal antibody solutions and its implications to solution viscosity Antibody therapeutics targeting ion channels: are we there yet?Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches Adnectins: engineered target-binding protein therapeutics Advantages of fluorescence-guided laparoscopic surgery of pancreatic cancer labeled with fluorescent anti-carcinoembryonic antigen antibodies in an orthotopic mouse model.

P2860

Q24601129-4529160C-C9DE-4596-87E1-1389B7FEDB0D Q26741062-8AC85C61-5C0C-4352-9432-0F9F5374F374 Q26801862-58D4B078-E6C9-4506-A55B-DB1FCC2F47B4 Q26822421-438FB684-4D71-4005-9AC8-5871D3258D8E Q26849947-EECCCE9D-8588-415E-BDC6-977FA0F78EC6 Q26863621-2C53823D-695C-4F7C-BDB2-F8551FE4D556 Q27006179-39017F4B-C6AF-4CFE-8EF7-DC71118C5B1D Q27025966-EE9E2AF2-FED0-467B-AA07-053229A49936 Q27308037-28939AAB-C096-407E-8A56-1C546D43ECE7 Q27667652-98090600-6133-464E-A98E-1C526F87C4BD Q27678251-E17C3E1D-D462-4E5B-932B-2FFF30E63536 Q27678732-9AC75AA4-BD53-4AB9-925B-06E2C08E086E Q28068946-A76A08C6-58BD-4E0E-BA5A-CE91E662C517 Q28082880-BE1B87EF-D9A4-4EBB-A7C5-601682D47C83 Q28086872-6E8ECADE-C3E5-473E-A900-66DE563712F6 Q28240662-E58A9149-F8C9-4ED6-9C22-A3FDE06FFED0 Q28394869-553070A2-EB44-449C-9C56-1661937BC063 Q28468281-44000E74-033F-4F45-A68B-D955C983F00A Q28484319-10D51375-C2C3-430A-9AFF-88A0B6F87769 Q28487387-F941F9C2-8487-4F02-BFC3-E06808B865BB Q28547051-DD3184B9-5976-44B6-8CD2-4C0031459E9B Q28818769-59FA859B-4396-43A3-B038-2061D140BF88 Q29399137-70F09AC7-0E86-4E00-8610-1FDC3865CF8A Q30240139-DA90DA49-950F-401F-98CD-30BB86750F73 Q30275229-EDDDF2F4-82B9-478D-A388-602911AE5746 Q30354666-0D28EDD9-A56C-4B6D-9134-C54757263DDF Q30360964-28035D2C-842F-4514-BA5A-DDC18A8B2B32 Q30368433-78EA246A-8C51-4151-8158-E0C3B828A6F8 Q30376735-55346126-B1FC-4DB3-999F-0B88CAFBDE6C Q30393523-F2FCEDE9-8EB1-44A8-97BB-107113D3F05C Q30398032-038F7BE4-FD53-448D-A653-FE2E5D368DE2 Q30414399-ADE5DB0C-2997-49FD-AFB7-7C902665CE30 Q30428210-14DF85E5-2EB6-42E8-A781-C68A20DF4436 Q30628296-7977FC05-E46A-46E6-8739-0C68805101B8 Q30993361-003E9D3D-9E71-47E3-B647-58BEB229BA65 Q33561503-B52106E0-DEA4-4471-AECA-DE053D868BC7 Q33572352-F145A2B9-257F-4BB2-8211-8ED5E28E9247 Q33641917-B39FA919-4DF2-4173-A016-9D200EF58869 Q33743756-50DE3169-A06E-4589-A771-9031B702EC47 Q33787300-1F459C04-7FDF-4A03-9C7B-AB5A710B265F

P2860

Strategies and challenges for the next generation of therapeutic antibodies.

http://www.wikidata.org/entity/Q34111699

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Strategies and challenges for the next generation of therapeutic antibodies.

@ast

Strategies and challenges for the next generation of therapeutic antibodies.

@en

Strategies and challenges for the next generation of therapeutic antibodies.

@nl

type

label

Strategies and challenges for the next generation of therapeutic antibodies.

@ast

Strategies and challenges for the next generation of therapeutic antibodies.

@en

Strategies and challenges for the next generation of therapeutic antibodies.

@nl

prefLabel

Strategies and challenges for the next generation of therapeutic antibodies.

@ast

Strategies and challenges for the next generation of therapeutic antibodies.

@en

Strategies and challenges for the next generation of therapeutic antibodies.

@nl

P1433

Q34111699-ECC976B0-C35D-4882-A92E-0789577366F6

P1476

Q34111699-5DD801A6-5337-4B61-B607-528732F032E0

P2093

Q34111699-1B3C79FE-688F-4C3B-84F8-A68A36A57106

Q34111699-2B7DA2D6-9AFF-4021-A141-302DCB64A2B6

Q34111699-2EBC1F09-437F-4FE7-824D-AD5DBF006456

Q34111699-9C01B5F5-D151-4F0D-993A-3C69A7B655E0

P2860

Q34111699-E2556A8F-469E-4511-87BD-CB22D66DA12C

P2888

Q34111699-3F87197C-8470-4B3E-A9FE-C7771E1A07B7

P304

Q34111699-7971B130-6C54-4435-8981-DE4794AD7498

P31

Q34111699-C1E276C1-8C9E-4AE7-A550-398463CD444E

P356

Q34111699-8955F24E-1BED-4A35-9A72-4D484FEE8691

P433

Q34111699-543EDDF2-F49F-49A6-A689-F0250C079A88

P478

Q34111699-0BAE04C2-FAB8-49ED-BBBB-374B79F38E44

P577

Q34111699-372F8724-6E11-4FA4-8E47-97F11C221B86

P5875

Q34111699-671CBC0A-59BA-4EEE-AF84-F50356626FC7

P6179

Q34111699-AD6087F4-77CC-4962-9EFA-5CD4844A30E2

P698

Q34111699-D811007E-30F6-4DEB-AD1C-853CF8E1069F

P921

Q34111699-FA248C42-BA61-4A06-B33F-94EC85C9721C

P356

P1433

Nature Reviews Immunology

P1476

Strategies and challenges for the next generation of therapeutic antibodies.

@en

P2093

Alain Beck

http://www.w3.org/2001/XMLSchema#string

Christian Bailly

http://www.w3.org/2001/XMLSchema#string

Nathalie Corvaia

http://www.w3.org/2001/XMLSchema#string

Thierry Wurch

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

P2888

P304

345-352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRI2747

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43299749

http://www.w3.org/2001/XMLSchema#string

P6179

1012486795

http://www.w3.org/2001/XMLSchema#string

P698

20414207

http://www.w3.org/2001/XMLSchema#string

P921